Fineline Cube

Follow:
14446 Articles
HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
CompanyDeals

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

CompanyDrug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
CompanyDeals

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Innovent Biologics' Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
Company

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Santen's Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China's NMPA for Myopia Progression
CompanyDrug

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

CompanyDeals

Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody

CompanyMedical Device

Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System

CompanyDrug

TenNor Therapeutics Reports Positive Phase IIa Top‑Line Results for TNP‑2092 in Prosthetic Joint Infection; First‑in‑Class Triple‑Target Candidate Advances to Phase IIb

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
CompanyDrug

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

CompanyDrug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

CompanyDeals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib